Currency in AUD
Last close As at 25/03/2023
AUD0.01
▲ −0.01 (−50.00%)
Market capitalisation
AUD99m
Research: Metals & Mining
On 11 April, Lepidico announced an updated global mineral resource estimate of 5.87Mt at 0.87% Li2O at Alvarrões in Portugal, of which two-thirds (by tonnage) is contained within pegmatites and the remaining third within a 0.5m mineralised halo within the granite host rock. Although the average grade of the resource appears to have decreased, this can be attributed to the inclusion of the halo within the estimate. Excluding it, the aggregate grade of the pegmatite mineralised units has actually risen. Moreover, whereas before 100% of the resource was classified in the lower-confidence inferred mineral resource category, in the updated estimate 44.3% resides within the indicated category.
Lepidico |
Alvarrões resource increases 290% |
Alvarrões resource update |
Metals & mining |
12 April 2019 |
Share price performance
Business description
Next events
Analyst
Lepidico is a research client of Edison Investment Research Limited |
On 11 April, Lepidico announced an updated global mineral resource estimate of 5.87Mt at 0.87% Li2O at Alvarrões in Portugal, of which two-thirds (by tonnage) is contained within pegmatites and the remaining third within a 0.5m mineralised halo within the granite host rock. Although the average grade of the resource appears to have decreased, this can be attributed to the inclusion of the halo within the estimate. Excluding it, the aggregate grade of the pegmatite mineralised units has actually risen. Moreover, whereas before 100% of the resource was classified in the lower-confidence inferred mineral resource category, in the updated estimate 44.3% resides within the indicated category.
Year end |
Total revenues (A$m) |
Reported PBT* |
Cash from operations (A$m) |
Net |
Capex |
06/17 |
0.1 |
(5.4) |
(3.6) |
3.3 |
(0.9) |
06/18 |
0.2 |
(7.2) |
(3.0) |
4.9 |
(3.1) |
06/19e |
0.0 |
(5.9) |
(6.2) |
24.3 |
(21.4) |
06/20e |
19.9 |
2.5 |
3.2 |
(5.2) |
(32.7) |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Feasibility study anticipated later this quarter
Lithium mineralisation in the pegmatites is dominated by lepidolite, which comprises c 10–15% of the pegmatites. The mineralisation within the 0.5m halo is dominated by zinnwaldite – another lithium-mica mineral, albeit one that is still amenable to processing via Lepidico’s proprietary L-Max® technology. Not only does the updated estimate represent a material increase over the December 2017 estimate, it also now exceeds the top end of our prior (non-JORC) estimate of 4.4Mt at a grade of 1.13% Li2O (see our note, Alvarrões continues to deliver, published on 4 October 2017), not least via the inclusion of a newly defined sill (denoted Sill P) down to a depth of 80m. As a result, we estimate that the Alvarrões resource now contains c 126,249t of lithium carbonate equivalent, which we value at US$4.4m (A$6.1m), or 0.18 Australian cents per share (see our note, Mining overview: Gold stars and black holes, Analysing the discount: From resource to sanction, published in January 2019). Of at least as much significance, however, is the fact that Alvarrões has now been confirmed as an extensive system of lithium-mineralised pegmatites of sufficient scale and quality to provide long-term lepidolite concentrate feed for Lepidico’s Phase 1 L-Max plant for well over 10 years and will contribute to a maiden ore reserve later this quarter.
Valuation: 6.84c/share potentially rising to 7.27c
As per our most recent Outlook note, Piloting its way through, published on 9 October 2018, we estimate that execution of a 7t/hour (5,000tpa) Phase 1 plant will result in free cash flow to Lepidico of A$71.2m per year once steady-state production has been achieved, which we value at A$0.0684/share assuming US$30m (A$41.8m) of equity financing at the prevailing share price or A$0.0727/share assuming a reduced US$21.2m in equity funding with a A$16.8m net debt funding requirement. Note that neither of these valuations ascribe any value to the Phase 2 plant or other development options.
Exhibit 1: Financial summary
Accounts: IFRS, Yr end: June, AUD: Thousands |
|
|
2015 |
2016 |
2017 |
2018 |
2019e |
2020e |
Total revenues |
|
|
9 |
116 |
127 |
171 |
16 |
19,948 |
Cost of sales |
|
|
0 |
0 |
0 |
0 |
(2,090) |
(11,170) |
Gross profit |
|
|
9 |
116 |
127 |
171 |
(2,074) |
8,778 |
SG&A (expenses) |
|
|
(455) |
(617) |
(912) |
(5,284) |
(3,868) |
(3,146) |
Other income/(expense) |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
Exceptionals and adjustments |
Exceptionals |
|
(16) |
(415) |
(878) |
(2,171) |
0 |
0 |
Depreciation and amortisation |
|
|
(5) |
(6) |
(6) |
(6) |
(9) |
(3,277) |
Reported EBIT |
|
|
(467) |
(923) |
(1,670) |
(7,290) |
(5,951) |
2,354 |
Finance income/(expense) |
|
|
(18) |
(5) |
128 |
70 |
24 |
121 |
Other income/(expense) |
|
|
(559) |
(448) |
(3,815) |
0 |
0 |
0 |
Exceptionals and adjustments |
Exceptionals |
|
0 |
(888) |
0 |
0 |
0 |
0 |
Reported PBT |
|
|
(1,044) |
(2,263) |
(5,357) |
(7,220) |
(5,927) |
2,476 |
Income tax expense (includes exceptionals) |
|
|
0 |
0 |
0 |
0 |
0 |
(619) |
Reported net income |
|
|
(1,044) |
(2,263) |
(5,357) |
(7,220) |
(5,927) |
1,857 |
Basic average number of shares, m |
|
|
178 |
465 |
1,802 |
2,624 |
3,803 |
4,705 |
Basic EPS |
|
|
(0.0) |
(0.0) |
(0.0) |
(0.0) |
(0.0) |
0.0 |
|
|
|
|
|
|
|
|
|
Balance sheet |
|
|
||||||
Property, plant and equipment |
|
|
9 |
4 |
8 |
27 |
21,390 |
50,794 |
Goodwill |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
Intangible assets |
|
|
0 |
16,204 |
16,698 |
19,027 |
19,027 |
19,027 |
Other non-current assets |
|
|
1,485 |
715 |
1,620 |
730 |
730 |
730 |
Total non-current assets |
|
|
1,494 |
16,922 |
18,326 |
19,783 |
41,147 |
70,551 |
Cash and equivalents |
|
|
53 |
650 |
3,307 |
4,860 |
24,288 |
24,288 |
Inventories |
|
|
0 |
0 |
0 |
0 |
1 |
1,662 |
Trade and other receivables |
|
|
4 |
3,886 |
706 |
712 |
1,176 |
1,640 |
Other current assets |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
Total current assets |
|
|
57 |
4,537 |
4,013 |
5,572 |
25,465 |
27,590 |
Non-current loans and borrowings |
|
|
0 |
0 |
0 |
0 |
0 |
29,486 |
Other non-current liabilities |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
Total non-current liabilities |
|
|
0 |
0 |
0 |
0 |
0 |
29,486 |
Trade and other payables |
|
|
105 |
614 |
1,663 |
804 |
991 |
1,177 |
Current loans and borrowings |
|
|
115 |
0 |
0 |
0 |
0 |
0 |
Other current liabilities |
|
|
40 |
33 |
46 |
51 |
51 |
51 |
Total current liabilities |
|
|
260 |
647 |
1,709 |
856 |
1,042 |
1,228 |
Equity attributable to company |
|
|
1,292 |
20,812 |
20,630 |
24,500 |
65,570 |
67,427 |
Non-controlling interest |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
|
|
|
|
|
|
|
|
|
Cashflow statement |
|
|
||||||
Profit for the year |
|
|
(1,044) |
(2,263) |
(5,357) |
(7,220) |
(5,927) |
1,857 |
Taxation expenses |
|
|
0 |
0 |
0 |
0 |
0 |
619 |
Depreciation and amortisation |
|
|
5 |
6 |
6 |
6 |
9 |
3,277 |
Share based payments |
|
|
450 |
40 |
1,736 |
2,138 |
0 |
0 |
Other adjustments |
|
|
(451) |
1,036 |
(162) |
2,066 |
0 |
0 |
Movements in working capital |
|
|
(10) |
132 |
133 |
(28) |
(279) |
(1,939) |
Interest paid / received |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
Income taxes paid |
|
|
0 |
0 |
0 |
0 |
0 |
(619) |
Cash from operations (CFO) |
|
|
(1,050) |
(1,049) |
(3,644) |
(3,038) |
(6,197) |
3,195 |
Capex |
|
|
(9) |
(63) |
(861) |
(3,057) |
(21,373) |
(32,681) |
Acquisitions & disposals net |
|
|
0 |
32 |
122 |
110 |
0 |
0 |
Other investing activities |
|
|
(563) |
(80) |
0 |
0 |
0 |
0 |
Cash used in investing activities (CFIA) |
|
|
(572) |
(111) |
(739) |
(2,947) |
(21,373) |
(32,681) |
Net proceeds from issue of shares |
|
|
1,505 |
1,872 |
7,040 |
7,555 |
46,998 |
0 |
Movements in debt |
|
|
100 |
(115) |
0 |
0 |
0 |
29,486 |
Other financing activities |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
Cash from financing activities (CFF) |
|
|
1,605 |
1,757 |
7,040 |
7,555 |
46,998 |
29,486 |
Increase/(decrease) in cash and equivalents |
|
|
(18) |
597 |
2,657 |
1,570 |
19,428 |
0 |
Currency translation differences and other |
|
|
0 |
0 |
0 |
(17) |
0 |
0 |
Cash and equivalents at end of period |
|
|
53 |
650 |
3,307 |
4,860 |
24,288 |
24,288 |
Net (debt) cash |
|
|
(61) |
650 |
3,307 |
4,860 |
24,288 |
(5,198) |
Movement in net (debt) cash over period |
|
|
(61) |
711 |
2,657 |
1,553 |
19,428 |
(29,486) |
Source: Company sources, Edison Investment Research
|
|
Research: Healthcare
Pixium Vision is developing Prima, a potentially breakthrough wireless sub-retinal implant that generates electrical impulses at the retinal bipolar cell level to restore a form of central visual perception. Pixium is on track to start an EU pivotal study for its Prima bionic vision system (BVS) in H219 for the treatment of advanced dry age-related macular degeneration (Dry-AMD) involving geographic atrophy (GA). This follows the release of positive six-month data in January 2019 for its five-patient EU feasibility study. Using a risk-adjusted NPV model, we obtain a pipeline rNPV (including net cash) of €99.5m, vs €99.0m previously.
Get access to the very latest content matched to your personal investment style.